ArticleInternational journal of clinical and experimental pathology2015
Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Expanding on roles of pleckstrin homology-like domain family A member 1 protein.Cell and tissue research · 2025Review
- Mutational signatures in 175 Chinese gastric cancer patients.BMC cancer · 2024Article
- PHLDA1 is a P53 target gene involved in P53-mediated cell apoptosis.Molecular and cellular biochemistry · 2024Article
- Effect of Obesity on the Expression of Genes Associated with Severe Asthma-A Pilot Study.Journal of clinical medicine · 2023Article
- PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras.Cellular and molecular life sciences : CMLS · 2022Article
- Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcomaFrontiers in genetics · 2022Article
- PHLDA1 expression in ulcerative colitis: A potential role in the management of dysplasia.Molecular and clinical oncology · 2021Article
- PHLD Class Proteins: A Family of New Players in the p53 Network.International journal of molecular sciences · 2020Review
- Circ0085539 Promotes Osteosarcoma Progression by Suppressing miR-526b-5p and PHLDA1 Axis.Frontiers in oncology · 2020Article
- PHLDA1, another PHLDA family protein that inhibits Akt.Cancer science · 2018Article
- PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.Cell reports · 2018Article
- Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples.Frontiers in immunology · 2018Article
- Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome.Nature communications · 2017Article
- Pleckstrin homology-like domain, family A, member 1 (Biomedical reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric carcinoma is one of the most aggressive malignancies with an extremely poor prognosis. Recent findings suggest decreasing PHLDA1 (pleckstrin-homologylike domain family A, member1) expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of PHLDA1 in gastric carcinoma remains to be determined.
methodsPHLDA1 protein was investigated by immunohistochemistry for the expression status in 336 cases of gastric adenocarcinomas and 60 normal mucosa, and then the results were analyzed with the patient's age, sex, tumor site, size and the histological grade, clinical stage as well as overall median survival time.
resultsThe expression of PHLDA1 protein was obviously decreased in 57.1% of gastric carcinomas. Carcinomas with loss of expression of PHLDA1 were significantly corresponding to with tumor size (P=0.037), grade (P=0.028), depth of invasion (P=0.001), lymph node metastasis (P=0.008) and stage (P=0.001) but not with age (P=0.194), sex (P=0.312), tumor site (P=0.287) and distal metastasis (P=0.331) respectively. Follow-up data showed that there was a significant difference in overall median survival time between the carcinomas with PHLDA1 negative expression (31.0 months) and those with positive expression (54.0 months) (P=0.001).
conclusionsOur findings suggest that the decreased expression of PHLDA1 may play an important role in tumor progression, and may become a new adjunct biomarker in the prognosis in gastric carcinoma. A potential role for PHLDA1 in the early detection/or therapy of gastric cancer warrants further investigation.
Indexed as
Identifiers
26191222PMC4503094W2417925437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.